Pricing Becomes Crucial Factor For Novo Nordisk’s Growth
This article was originally published in The Pink Sheet Daily
The Danish diabetes drug maker is a commanding player in the market, but pushback from reimbursement authorities around the world is placing the company’s future growth prospects under scrutiny.
You may also be interested in...
Newer drugs at Bayer helped the bottom line in the third quarter while the world’s top insulin maker Novo Nordisk missed expectations, but held out emerging markets as a bright spot. Teva tussled with analysts on the surprise exit of Jeremy Levin and said that many of the plans during his brief tenure were driven by the board and remain in place.
Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.